PURPOSE: There is an increasing interest for dose differentiation in prostate radiotherapy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The purpose of our study was to analyze the spatial distribution of tumor satellites inside the prostate.
METHODS AND MATERIALS: 61 prostatectomy specimens were stained with H&E. Tumor regions were delineated by the uro-pathologist. Volumes, distances and cell densities of all delineated tumor regions were measured and further analyzed.
RESULTS: Multifocal disease was seen in 84% of the patients. The median number of tumor foci was 3. The median distance between the index lesion and the satellites was 1.0cm, with a maximum of 4.4cm. The index lesions accounted for 88% of the total tumor volume. The contribution of tumor foci< 0.1cm3 to the total tumor volume was 2%. The median cell density of the index lesion and all satellites, regardless of size, were significantly higher than that of the prostate.
CONCLUSIONS: Satellites do not appear in a limited margin around the index lesion (GTV). Consequently, a fixed CTV margin would not effectively cover all satellites. Thus if the aim is to treat all tumor foci, the entire prostate gland should be considered CTV.
Hollmann BG, van Triest B, Ghobadi G, Groenendaal G, de Jong J, van der Poel HG, van der Heide UA. Are you the author?
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Reference: Radiother Oncol. 2015 Mar 18. pii: S0167-8140(15)00120-6.